A Novel Delivery Method of Cyclovirobuxine D for Brain-Targeting: Chitosan Coated Nanoparticles Loading Cyclovirobuxine D by Intranasal Administration

Abstract

The blood-brain barrier (BBB) restricts the delivery of most drugs to the brain. In our previous study, the feasibility of cyclovirobuxine D delivery to the brain by a non-invasive nasal route was evaluated. In this study, a suitable drug delivery system by way of intranasal administration was developed, which could improve brain targeting. First, a formulation of cyclovirobuxine D (CVB-D) based on chitosan nanoparticles (CS-CVB-D-NPs) was prepared by the modified ionotropic gelation method through single-factor screening experiment. The CS-CVB-D-NPs with a entrapment efficiency (EE) of (62.82±2.59)% were found to be of a narrow polydispersity index (PI) (0.19±0.01) and (235.37± 12.71) nm in size, with a zeta potential of (33.9 ± 1.7) mV. The NPs possessed a sustained release characterization with in vitro release of 88.03 ± 2.30% at 24 h. In vivo, the higher AUC0-t(brain) of CS-CVB-D-NPs by intranasal administration revealed the development of a novel brain-targeting delivery method of CVB-D.

Toxicity, morphological and structural properties of chitosan‐coated Bi 2 O 3 –Bi(OH) 3 nanoparticles prepared via DC arc discharge in liquid: a potential nanoparticle‐based CT contrast agent

“…For instance, they enable targeting biomarkers, tumour-targeting CT imaging, dual CT/optical cancer imaging, liver-specific CT imaging and multimodal imaging [41][42][43]. Because of chitosan surface modification ability, it has drawn considerable attention [44,45]. Chitosan is a polysaccharide that derives from chitin.…”

Chitosan Nanoparticles for Intranasal Drug Delivery

“…These nanoparticles demonstrated sustained release over 24 h and increased brain targeting via intranasal administration. The ability to increase brain concentration of cyclovirobuxine D indicates an effective brain-targeting delivery method, which could enhance treatment outcomes for cognitive impairments [ 12 ]. Lastly, polylactic acid nanoparticles were modified with chitosan to encapsulate a neurotoxin labeled with fluorescein isothiocyanate.…”

“…Chemical Cross-linking : To further stabilize the nanostructures and control the release of loaded agents, chitosan nanoparticles can be cross-linked using various agents. For example, the use of tripolyphosphate for ionic cross-linking of chitosan nanoparticles is a common approach to enhance their stability under physiological conditions [ 12 ].…”